|
|
Article: Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin.
- Article from:
- PR Newswire
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Marks significant advance in Simcere's portfolio of cardiovascular drugs
NANJING, China, Nov. 9 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical Co., Ltd. ("Tianda"). The acquisition of the manufacturing license will be effected through the acquisition of equity in Tianda as well as transfer of certain technologies from Tianda. Rosuvastatin was first ...